Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced ...

Novartis’ immunology drug Cosentyx (secukinumab) notched its sixth indication, gaining U.S. approval as a hidradenitis suppurativa (HS) therapy, the drugmaker said this week. The regulatory OK makes ...

The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...

The FDA has approved Cosentyx® (secukinumab; Novartis) for the treatment of adults with active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. The Food and ...

Novartis’ psoriasis drug, Cosentyx (secukinumab) received a boost after data showed it is better at clearing skin than Johnson & Johnson’s rival Stelara. Cosentyx is one of several newer drugs that ...

Novartis’ Cosentyx has a head start on the next-gen psoriasis pack, but the company is still gunning to build its lead before a raft of new competitors arrive. And now, the Swiss drugmaker has some ...

Cosentyx for Plaque Psoriasis Approved Novartis announced that the Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of moderate to severe plaque psoriasis in ...

Beating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting drugs in the immunology market, but Novartis’ Cosentyx has just fallen short on ...

It looks like AbbVie has the trial win it was hoping for to unlock the psoriasis market for its recently-approved psoriasis therapy Skyrizi. The head-to-head study pitted IL-23 antagonist Skyrizi ...

Novartis’ interleukin-17A (IL-17A) Cosentyx (secukinumab) demonstrated early synovitis reduction in patients with active psoriatic arthritis in the phase IIIb ULTIMATE study. Synovitis, or joint ...

Cosentyx (secukinumab) may be safe to use while pregnant or breastfeeding. Before starting treatment, you and your doctor can discuss the risks and benefits of Cosentyx treatment during pregnancy or ...

Novartis has unveiled more positive phase 3 data for Cosentyx, this time in patients with non-radiographic axial spondyloarthritis (nr-axSpA). The Swiss drugmaker has strengthened Consentyx’s ...